TuHURA Biosciences Reports Initial Data from Open-Label Study of IFx-2.0 in Metastatic Merkel Cell Carcinoma

Initial Results Shared from Open-Label Trial

TuHURA Biosciences, Inc., a Phase 3 immuno-oncology company trading under the ticker NASDAQ: HURA, announced initial data from the first three patients enrolled in its open-label study evaluating IFx-2.0 as an adjunctive therapy to Keytruda (pembrolizumab). The study focuses on the first-line treatment of adult patients with deep-seated metastatic Merkel Cell Carcinoma (MCC).

According to the announcement, the preliminary results demonstrated major objective anti-tumor responses in the first three patients at the six-month assessment mark. All three patient responses met the criteria for a partial response under RECIST v.1.1 guidelines and were noted as ongoing and durable at the protocol-specified six-month evaluation.

Trial Design and Administration

The ongoing Phase 1b/2a clinical trial is a multicenter, open-label study designed to examine the safety and feasibility of administering IFx-2.0 alongside Keytruda. The study specifically targets patients with deep-seated and/or bulky visceral tumors—such as those located in the hepatic, pulmonary, or retroperitoneal regions—where standard-size injection needles typically cannot effectively deliver the intended dose without image guidance, such as CT or ultrasound.

In the trial protocol, patients receive 0.1 mg of IFx-2.0 injected into a single deep-seated or bulky tumor once weekly for three weeks. Within 48 hours following the initial IFx-2.0 injection, patients receive Keytruda, followed by subsequent doses of Keytruda every three weeks until disease progression, toxicity, or a duration of two years is reached. Keytruda is currently approved as a front-line standard of care for patients with advanced or metastatic MCC.

Executive Commentary and Next Steps

Dr. James Bianco, President and Chief Executive Officer of TuHURA Biosciences, noted the significance of utilizing image-guided administration safely in patients with bulky, deep-seated tumors.

"While preliminary and only reported in 3 patients, these results highlight that it is feasible to utilize CT or ultrasound guided administration of IFx-2.0 safely to patients with large bulky and or deep-seated tumors," said Dr. Bianco in the official announcement. He added that if high response rates continue, the company may explore expanding the patient enrollment in the trial and discussing potential pathways with the U.S. Food and Drug Administration (FDA).

The primary endpoint of the trial measures safety and feasibility 28 days following the final dose of IFx-2.0, corresponding to 49 days from the initial infusion. Secondary endpoints include efficacy evaluated via RECIST 1.1 criteria at three and six months.

Practical Implications and Verification

Readers, investors, and healthcare professionals tracking these developments should note the following breakdown of confirmed details versus ongoing uncertainties:

• Confirmed Details: Initial data covers only the first three patients in an open-label, multicenter trial setting. All three demonstrated partial responses meeting RECIST v.1.1 criteria at six months. The trial evaluates the combination of IFx-2.0 with Keytruda for front-line metastatic MCC.
• What Remains Unknown: The long-term safety and broader efficacy across the entire planned cohort of nine patients remain to be determined. Whether these preliminary response rates will translate into the larger randomized, placebo-controlled Phase 3 registration trial is not yet established.
• How to Verify: Readers can review the original press release and company updates directly through [PR Newswire](https://www.prnewswire.com/news-releases/tuhura-biosciences-provides-first-look-at-data-from-its-open-label-study-of-ifx-2-0-as-an-adjunctive-therapy-to-keytruda-in-first-line-treatment-of-patients-with-deep-seated-metastatic-merkel-cell-carcinoma-302918838.html) or visit the investor relations section of the official TuHURA Biosciences website.